August F Holtyn1, Barbara J Kaminski1, Elise M Weerts2. 1. Johns Hopkins University School of Medicine, USA. 2. Johns Hopkins University School of Medicine, USA. Electronic address: eweerts@jhmi.edu.
Abstract
BACKGROUND: Baclofen, a GABAB receptor agonist, is under investigation as a pharmacotherapy for alcohol use disorder. Treatment with a pharmacotherapeutic can be initiated during alcohol abstinence or active drinking, which may influence treatment outcomes. This study examined whether baclofen treatment initiated and maintained during alcohol abstinence would reduce alcohol seeking and self-administration upon return to alcohol access, and whether effects differed from treatment initiated and maintained during ongoing alcohol access. Naltrexone was tested under similar conditions for comparison. METHODS: Five baboons self-administered alcohol under a three-component chained schedule of reinforcement that modeled periods of anticipation (Component 1), seeking (Component 2), and consumption (Component 3). Alcohol was only available in Component 3. In Experiment 1, baclofen (0.1-1.8mg/kg) or naltrexone (1.0-5.6mg/kg) was administered daily beginning on the first day of a 5-day abstinence period and treatment was continued for 5days of alcohol access. In Experiment 2, selected doses of both drugs were administered during ongoing alcohol access. RESULTS: When treatment was initiated during alcohol abstinence, baclofen and naltrexone did not significantly reduce total alcohol intake (g/kg) or alcohol seeking. In comparison, when treatment was initiated during ongoing alcohol access, both baclofen (1.8mg/kg) and naltrexone (3.2 and 5.6mg/kg) significantly reduced total alcohol intake (g/kg). Naltrexone (5.6mg/kg), but not baclofen, significantly reduced alcohol seeking. CONCLUSIONS: Initiation of baclofen treatment (or other alcohol use disorder treatments) during abstinence or active drinking may be an important factor in influencing efficacy and appropriate dose selection.
BACKGROUND:Baclofen, a GABAB receptor agonist, is under investigation as a pharmacotherapy for alcohol use disorder. Treatment with a pharmacotherapeutic can be initiated during alcohol abstinence or active drinking, which may influence treatment outcomes. This study examined whether baclofen treatment initiated and maintained during alcohol abstinence would reduce alcohol seeking and self-administration upon return to alcohol access, and whether effects differed from treatment initiated and maintained during ongoing alcohol access. Naltrexone was tested under similar conditions for comparison. METHODS: Five baboons self-administered alcohol under a three-component chained schedule of reinforcement that modeled periods of anticipation (Component 1), seeking (Component 2), and consumption (Component 3). Alcohol was only available in Component 3. In Experiment 1, baclofen (0.1-1.8mg/kg) or naltrexone (1.0-5.6mg/kg) was administered daily beginning on the first day of a 5-day abstinence period and treatment was continued for 5days of alcohol access. In Experiment 2, selected doses of both drugs were administered during ongoing alcohol access. RESULTS: When treatment was initiated during alcohol abstinence, baclofen and naltrexone did not significantly reduce total alcohol intake (g/kg) or alcohol seeking. In comparison, when treatment was initiated during ongoing alcohol access, both baclofen (1.8mg/kg) and naltrexone (3.2 and 5.6mg/kg) significantly reduced total alcohol intake (g/kg). Naltrexone (5.6mg/kg), but not baclofen, significantly reduced alcohol seeking. CONCLUSIONS: Initiation of baclofen treatment (or other alcohol use disorder treatments) during abstinence or active drinking may be an important factor in influencing efficacy and appropriate dose selection.
Authors: G Colombo; R Agabio; M A Carai; C Lobina; M Pani; R Reali; G Addolorato; G L Gessa Journal: Alcohol Clin Exp Res Date: 2000-01 Impact factor: 3.455
Authors: Giancarlo Colombo; Salvatore Serra; Giuliana Brunetti; Giovanni Vacca; Mauro A M Carai; Gian Luigi Gessa Journal: Drug Alcohol Depend Date: 2003-05-01 Impact factor: 4.492
Authors: Giancarlo Colombo; Giovanni Vacca; Salvatore Serra; Giuliana Brunetti; Mauro A M Carai; Gian Luigi Gessa Journal: Psychopharmacology (Berl) Date: 2003-04-01 Impact factor: 4.530
Authors: Giovanni Addolorato; Fabio Caputo; Esmeralda Capristo; Marco Domenicali; Mauro Bernardi; Luigi Janiri; Roberta Agabio; Giancarlo Colombo; Gian Luigi Gessa; Giovanni Gasbarrini Journal: Alcohol Alcohol Date: 2002 Sep-Oct Impact factor: 2.826
Authors: Giancarlo Colombo; Salvatore Serra; Giuliana Brunetti; Giuliana Atzori; Marialaura Pani; Giovanni Vacca; Giovanni Addolorato; Wolfgang Froestl; Mauro A M Carai; Gian Luigi Gessa Journal: Alcohol Alcohol Date: 2002 Sep-Oct Impact factor: 2.826
Authors: Daria Piacentino; Silvia Grant-Beurmann; Carlotta Vizioli; Xiaobai Li; Catherine F Moore; Victor Ruiz-Rodado; Mary R Lee; Paule V Joseph; Claire M Fraser; Elise M Weerts; Lorenzo Leggio Journal: Transl Psychiatry Date: 2021-12-01 Impact factor: 6.222
Authors: Michael C Salling; Alexander Grassetti; Vincent P Ferrera; Diana Martinez; Richard W Foltin Journal: Pharmacol Biochem Behav Date: 2021-07-02 Impact factor: 3.697
Authors: Mehdi Farokhnia; Sara L Deschaine; Armin Sadighi; Lisa A Farinelli; Mary R Lee; Fatemeh Akhlaghi; Lorenzo Leggio Journal: Mol Psychiatry Date: 2018-10-31 Impact factor: 15.992